Pharmaceuticals
LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma
MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration[1] Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses[2] SINGAPORE, June 27, 2023 /PRNewswire/ -- Independent biopharmaceutical ...
2023-06-28 04:00
1702
First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed
* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S andChina. * The first human patients were dosed with the drug. * This is a potentially first-in-class an...
2023-06-27 21:00
2494
EXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TEST
* INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) * The results of a comprehensive 483-sample case-control study established that INOVIQ's SubB2M/CA15-3 blood test significantly outperformed a ...
2023-06-27 19:00
1849
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu
and WuXi Biologics officially entered into a global strategic cooperation for
the Singapore CRDMO Center project of WuXi Biologics.
2023-06-27 15:33
2169
Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy
SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of itsUSD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Grou...
2023-06-27 08:30
2573
CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer
* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland China, and the eleventh new drug application approval that CStone has obtained inGreater China overall. * In the ARROW study, GAVRETO had demonstrate...
2023-06-27 08:05
2177
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRC...
2023-06-27 03:51
1865
HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research
CHENGDU, China, June 26, 2023 /PRNewswire/ -- HitGen Inc. ("HitGen", SSE: 688222.SH) has recently launched a newly upgraded version of its OpenDEL™ product, a self-service screening kit for novel molecules. It contains 65% more DEL libraries than the previous version, and with over 3 billion comp...
2023-06-26 21:30
2123
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...
2023-06-26 08:10
2614
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-06-26 08:00
3144
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...
2023-06-26 07:30
2269
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...
2023-06-25 20:00
2846
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
* Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients * On-going Phase 3 clinical trials in Chinese patients with type 2 diabetes and obesity have achieved target enroll...
2023-06-24 10:00
4169
SK pharmteco doubles viral vector production capacity in Europe
* Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to10,000m2, one of the largest inEurope * Operation of the second facility to kick sta...
2023-06-23 07:30
2078
Bergen Conference Marks 150 Years Since Discovery of the Leprosy Bacillus
TOKYO, June 22, 2023 /PRNewswire/ -- A two-day conference commemorating the discovery of the bacillus that causes leprosy 150 years ago took place in Bergen, Norway, on June 21-22, 2023. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative and the University of Bergen, the conference i...
2023-06-22 22:00
2151
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target ...
2023-06-22 21:53
2519
I-Mab Announces the Appointment of Raj Kannan as CEO
GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan...
2023-06-22 20:00
2235
PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DS...
2023-06-22 19:00
1771
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
2352
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
1928
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5790
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4447
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4039
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3320
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3064